Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

ion with methotrexate. In preclinical studies, Rigel's R788 was shown to diminish the swelling and tissue destruction associated with RA. In addition, in a murine model of ITP, R788 was shown to increase platelet counts significantly.

Lymphoma is a large class of blood cancers that affect the lymphoid system, which is part of the immune system. In 2006, lymphoma affected an estimated 500,000 people in the United States, with 332,000 of them suffering from non-Hodgkin's varieties of the disease. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma and is generally categorized as aggressive, marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow and other organs.

A variety of treatment options exist, including chemotherapy and radiation, but the five-year survival rate for non-Hodgkin's lymphoma patients is estimated to be around 50%. Even for those who respond to treatment, recurrence of the disease is common.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates, the timing of results thereof and the potentia
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:3/27/2015)... BROOKFIELD, Wis. , March 27, 2015 /PRNewswire/ ... 40,000 unit shipments of incontinence devices for women. ... terrific, but the most gratifying part is the ... receive from women whose lives have been positively ... , president of InControl. InControl recently ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 14, 2011 Berger Health System, recognized as one ... Association, upgrades to AutoCarousel® HD by Talyst, a leader ... control, and has a built-to-last 10 years guarantee. ... five years, is also implementing AutoPharm®, AutoPack™ and AutoLabel® ...
... Dec. 14, 2011 Lineagen, Inc., an innovative molecular ... Fast Forward, LLC, a nonprofit subsidiary of the National ... the clinical development and validation of a blood-based assay ... is to develop a test that can aid clinicians ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:3/29/2015)... Viejo, California (PRWEB) March 29, 2015 ... revealed a new transition from Pixel Film Studios, entitled ... sports transitions made exclusively for Final Cut Pro X,” ... given our users the tools needed to effortlessly transition ... Studios introduces TranSports, a new and uniquely styled transition ...
(Date:3/28/2015)... Bellingham, WA (PRWEB) March 28, 2015 ... for athletes, recently announced the release of their new natural ... ounce and 3 ounce packages. Both options come with ... be purchased at RocketPure.com or on Amazon. Click ... product description states that the natural sunscreen is made with ...
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... New York (PRWEB) March 28, 2015 ... ) involving devices manufactured by C.R. Bard, Inc. ... underway in U.S. District Court, Southern District of ... Grand, is serving on the Plaintiffs’ Steering Committee. ... the Court has granted certain defendants named in ...
(Date:3/28/2015)... India Network visitor health insurance ... all visitors who purchase the plan before arrival in ... to purchase the insurance program as soon as travel ... for pre-existing medical conditions. Parents and grandparents traveling from ... with serious consequences to their health. Many visitors may ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... with Osiris on a Phase II Trial to Evaluate ... , New York, NY October 25, ... a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support ... cell therapy product, to preserve and regenerate insulin-producing cells ...
... the Result of Alliance with Dr. James Levine ... 25 Steelcase Inc. (NYSE: SCS ),a ... height-adjustable workstation with an integrated treadmill, at its ... product from the,FitWork(TM) category of products designed to ...
... 25 In its first-ever,single-topic special issue, the ... issue offers advice aimed at unscrambling the mixed,messages ... latest,research on nutrition, its recommendations include:, -- ... Along with exercise,fruits and vegetables are the closest ...
... On-the-go snacking and mobile devices more appetizing than ... Americans increasingly are,attached to portable devices such as ... into eat-and-run mode. According to a,recent survey(1) conducted ... http://www.ZonePerfect.com ), nearly one in three Americans ages ...
... (Nasdaq: THOR ), a world leader in products ... its operating,results for the third quarter of fiscal 2007 ... a conference call to discuss its financial,results and operating ... Daylight Time (11:30 a.m., Eastern Daylight Time), Thursday,November 1, ...
... help to improve the use of anti-cancer drugs designed to ... process called angiogenesis that is critical to tumor growth. While ... reliable methods for determining whether they are working, if the ... (or not) from treatment. , A team led by ...
Cached Medicine News:Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:Steelcase Unveils the Walkstation to Bring Healthy Habits to The Workplace 2Health News:Steelcase Unveils the Walkstation to Bring Healthy Habits to The Workplace 3Health News:All About Heart-Healthy Eating: The Harvard Heart Letter Devotes an Issue to Nutrition 2Health News:ZonePerfect(R) Survey Finds Americans Are Overfed on Technology, Underfed at the Dinner Table 2Health News:ZonePerfect(R) Survey Finds Americans Are Overfed on Technology, Underfed at the Dinner Table 3Health News:Thoratec Schedules Third Quarter Conference Call, Webcast 2Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 2Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: